香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年6月30日止三個月之 第一季度業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年6月30日止三個月之未經審核簡明綜合第一季度業績連 同去年同期之未經審核比較數字。本公告載有本公司2023/24第一季度報告全文，符合聯 交所GEM證券上市規則（「GEM上市規則」）有關隨附第一季度業績初步公告的資料的相關 規定。 本公告刊載於聯交所網站(www.hkexnews.hk)及本公司網站(www.medicskinholdings.com)。 本公司2023/24第一季度報告印刷本將適時寄發予本公司股東，並於本公司及聯交所網站可 供查閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 ...

Environmental Impact - Total greenhouse gas emissions for 2023 were 52,136 kg (CO2 equivalent), an increase from 48,413 kg in 2022, with emissions per employee rising to 1,212 kg from 1,181 kg[12]. - Scope 2 emissions from purchased electricity amounted to 45,363 kg in 2023, up from 42,792 kg in 2022[12]. - The density of greenhouse gas emissions per million HKD of total revenue increased to 1,145 kg in 2023 from 986 kg in 2022[12]. - The company produced 672 kg of indirect emissions from paper waste disposal in 2023, compared to 576 kg in 2022[12]. - The company generated approximately 39 kg of medical waste per employee in 2023, a decrease from 41 kg in 2022, with a density of 0.9 kg per million HKD of total revenue[16]. - The company is committed to sustainable long-term actions to manage its carbon footprint and reduce emissions[13]. - The company has not faced any environmental claims, lawsuits, or penalties during the reporting period[9]. - The company has implemented energy-saving measures, including monitoring indoor temperatures and upgrading to energy-efficient LED lighting[13]. - The company aims to maintain a comfortable indoor temperature of 25 degrees Celsius to balance comfort and energy consumption[13]. - The company has implemented waste reduction strategies and promotes recycling and waste segregation to minimize environmental impact[31]. - The company is committed to managing medical waste carefully, adhering to local regulations regarding waste disposal[26]. - The company has installed HEPA air purifiers in its Medicskin centers to improve indoor air quality[114]. - The group is committed to long-term sustainability by minimizing environmental impact through energy and water conservation efforts[137]. Financial Performance - The company's revenue for the fiscal year ending March 31, 2023, was HKD 45.5 million, a decrease of 7.3% from HKD 49.1 million in the previous fiscal year[49]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, compared to a profit of HKD 3.9 million in the previous fiscal year, primarily due to a revenue decrease of approximately HKD 3.6 million and a foreign exchange loss of HKD 1.4 million[56]. - Other income and net gains decreased from HKD 1.2 million for the year ended March 31, 2022, to HKD 0.5 million for the year ended March 31, 2023, primarily due to a foreign exchange loss of HKD 1.4 million[59]. - Inventory costs increased to HKD 8.9 million for the year ended March 31, 2023, from HKD 7.0 million for the year ended March 31, 2022, representing 19.5% and 14.3% of the group's revenue for the respective years[60]. - Employee costs rose by HKD 2.0 million or 9.5% to HKD 22.5 million for the year ended March 31, 2023, attributed to increased salaries and performance bonuses for doctors[61]. - The group recorded a loss attributable to owners of HKD 3.0 million for the year ended March 31, 2023, compared to a profit of HKD 3.9 million for the year ended March 31, 2022[89]. - Total equity as of March 31, 2023, was HKD 11.2 million, down from HKD 14.2 million as of March 31, 2022[92]. - Cash and bank balances decreased to HKD 5.0 million as of March 31, 2023, from HKD 14.2 million as of March 31, 2022[92]. - The group did not declare a final dividend for the year ended March 31, 2023[91]. - The group had no interest-bearing borrowings as of March 31, 2023, resulting in a debt-to-equity ratio of zero[92]. - Operating cash generated for the year ended March 31, 2023, was HKD 4.3 million, unchanged from 2022[93]. - As of March 31, 2023, the group's lease liabilities were HKD 11.9 million, down from HKD 18.7 million in 2022[93]. - The group has unused bank financing of HKD 18.0 million under the SME Financing Guarantee Scheme as of March 31, 2023, compared to none in 2022[93]. - The capital commitment for injection to subsidiaries was HKD 0.5 million as of March 31, 2023, down from HKD 0.6 million in 2022[97]. - The group has no major investments or capital asset plans as of March 31, 2023[95]. Market and Business Strategy - The group aims to reduce emission intensity by 5% to 10% by 2023, using the fiscal year ending in 2018 as the baseline[26]. - The introduction of the EMFACE® treatment, a revolutionary facial treatment using RF and HIFESTM technology, aims to enhance service offerings and maintain competitiveness in the skincare industry[25]. - The reopening of the border between mainland China and Hong Kong is expected to attract more tourists, potentially positively impacting the group's revenue[26]. - The group plans to continue exploring and launching various new services and products to increase market share and create value for shareholders[25]. - The company plans to strategically expand and strengthen its market share in Hong Kong and mainland China while continuously improving service and product quality[51]. - The company aims to introduce new services and products as a key driver for business growth and to maintain its competitive position in the industry[57]. - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products to adapt to the new normal[53]. - The company continues to evaluate market developments in new products, skills, and treatment technologies to provide the most suitable services to customers[57]. Employee and Training - The group has maintained a zero record for work-related injuries and fatalities during the reporting period[112]. - The company provided a total of 235 hours of training for employees during the reporting period, an increase from 171.5 hours in 2022[118]. - 100% of doctors and senior management participated in training, while 50% of general staff and 95% of medical assistants were trained[118]. - The average training hours completed per employee were 11.5 hours for male doctors and 7 hours for female doctors[118]. - The group had a total of 43 employees as of March 31, 2023, compared to 41 employees in the previous year[72]. - As of March 31, 2023, the group employed 28 full-time and 15 part-time employees, with total employee costs amounting to HKD 22.5 million, an increase from HKD 20.5 million in 2022[133]. Governance and Compliance - The group has complied with all relevant laws and regulations regarding environmental protection, health and safety, and employment during the reporting period[138]. - The company has established a whistleblowing policy to report misconduct, ensuring confidentiality and protection for whistleblowers[163]. - The company has received annual confirmation letters regarding the independence of all independent non-executive directors as per GEM Listing Rule 5.09[181]. - The group has maintained effective governance practices, ensuring the independence of its board members and adherence to regulatory requirements[181][184]. - The company has not been aware of any corruption lawsuits against it or its employees during the reporting period[161]. - The company has complied with the Prevention of Bribery Ordinance (Cap. 201) for the year ended March 31, 2023[164]. - Over 40% of employees have attended anti-corruption training provided by the Hong Kong Independent Commission Against Corruption[160]. - The company has established a clear recruitment process to comply with legal requirements and verify candidates' qualifications[119]. Community Engagement - The company donated HKD 3,000 to the Bright Eyes Engineering Charity Fund, demonstrating its commitment to positively impacting the community[186]. - The company emphasizes the importance of community engagement and resource utilization to support organizations driving positive social change[186].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年3月31日止年度之 全年業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年3月31日止年度之全年業績連同去年之比較數字。本 公告載有本公司2022/23年年度報告全文，符合聯交所GEM證券上市規則（「GEM上市規 則」）有關隨附全年業績初步公告的資料的相關規定。 本 公 告 刊 載 於 聯 交 所 網 站 (www.hkexnews.hk) 及 本 公 司 網 站 (www.medicskinholdings.com)。本公司2022/23年年度報告印刷本將適時寄發予本公司股 東，並於本公司及聯交所網站可供查閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 江覺亮醫生 ...

Financial Performance - The company reported a loss attributable to owners of the company of HKD 3.1 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.2 million for the same period in 2021, primarily due to a decrease in revenue of approximately HKD 8.3 million or 20.5%[13] - Basic loss per share for the period was HKD 0.79, compared to a basic earnings per share of HKD 0.81 for the same period last year[13] - The company’s total revenue for the nine months ended December 31, 2022, was HKD 31.9 million, a decrease from HKD 40.2 million in the same period last year[58] - The group recorded a net loss of HKD 3.14 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.22 million in the same period of 2021[77] - The group's revenue decreased by HKD 8.3 million or 20.5% to HKD 31.9 million for the nine months ended December 31, 2022, compared to HKD 40.2 million for the same period in 2021[83] Revenue Breakdown - Revenue from medical consultation services for the three months ended December 31, 2022, was HKD 227,000, a decrease of 26% from HKD 306,000 in the same period of 2021[62] - Revenue from prescription and dispensing services for the nine months ended December 31, 2022, was HKD 6.94 million, down 10.6% from HKD 7.76 million in the same period of 2021[62] - Revenue from medical consultation services, prescription and dispensing services, and treatment services were HKD 0.7 million, HKD 6.9 million, and HKD 24.3 million, respectively, accounting for 2.3%, 21.7%, and 76.0% of total revenue[108] Cost and Expenses - The cost of inventory for the group was HKD 6.1 million and HKD 6.2 million for the nine months ended December 31, 2022, and 2021, respectively, representing 19.0% and 15.5% of the group's revenue for the respective periods[15] - Other expenses decreased by HKD 0.7 million or 10.6% compared to the nine months ended December 31, 2021, which amounted to HKD 6.5 million[17] - Employee costs decreased by HKD 1.8 million or 10.8% to HKD 15.5 million for the nine months ended December 31, 2022, primarily due to reduced salaries and bonuses[38] Future Outlook - The company maintains a cautious optimism regarding future performance, anticipating a significant rebound in local consumer sentiment and sales due to the lifting of COVID-19 restrictions[14] - The company aims to continue providing high-quality medical skin care services and products while seeking new business opportunities to enhance its market position and maximize returns for investors[14] - The group believes that introducing new services and products is one of the key drivers for business growth and maintaining competitiveness[109] Market Presence - The company’s revenue from external customers is primarily derived from Hong Kong, indicating a focused market presence[28] - The company has a solid customer base, with most clients having been with the company for over five years, contributing to its revenue stability[12] - The group did not have any individual customer contributing more than 10% of total revenue during the nine months ended December 31, 2022[9] Operational Developments - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products in response to the pandemic[35] - The group continues to face intense market competition and the negative impact of the COVID-19 pandemic[80] - The group will continue to conduct market research on the latest products, skills, and medical instruments and technologies[109] Governance and Compliance - The audit committee currently consists of two independent non-executive directors, ensuring compliance with GEM listing rules[123] - The company has established an audit committee and has developed a written terms of reference in accordance with GEM listing rules[123] - The company is committed to appointing sufficient independent non-executive directors to meet the minimum requirements of GEM listing rules within three months from November 15, 2022[121] Other Financial Information - The company did not recommend the payment of an interim dividend for the nine months ended December 31, 2022, consistent with the previous year[31] - Interest income from bank deposits for the nine months ended December 31, 2022, was HKD 233,000, an increase of 6.4% from HKD 219,000 in the same period of 2021[64] - The group received government grants amounting to HKD 829,000 for the nine months ended December 31, 2022[64] - The group reported a foreign exchange loss of HKD 1.52 million for the nine months ended December 31, 2022, compared to a gain of HKD 432,000 in the same period of 2021[64] - The group has not recognized any provision for Hong Kong profits tax due to estimated taxable profits being offset by estimated prior tax losses[86] - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ended December 31, 2022[47] - As of December 31, 2022, the group's current liabilities net amount was HKD 3.2 million, primarily from contract liabilities of HKD 20.1 million[61] - As of December 31, 2022, no share options were exercised or cancelled, and 4,000,000 share options expired[95] - The company has adopted a share option scheme to reward eligible individuals for their contributions to the group[23]

Financial Performance - Revenue for the six months ended September 30, 2022, was HKD 20,021,000, a decrease of 24.5% compared to HKD 26,618,000 for the same period in 2021[4] - The company reported a loss of HKD 3,331,000 for the six months ended September 30, 2022, compared to a profit of HKD 1,900,000 for the same period in 2021[4] - Basic loss per share for the six months ended September 30, 2022, was HKD (0.63), compared to HKD 0.06 for the same period in 2021[6] - The group reported a loss of HKD (3,305) thousand in total comprehensive income for the period, compared to a loss of HKD (3,313) thousand in the previous year[11] - For the six months ended September 30, 2022, the company reported a loss attributable to owners of the company of HKD 3,305,000, compared to a profit of HKD 1,755,000 for the same period in 2021[33] - The group recorded a loss attributable to owners of the company of HKD 3.3 million for the six months ended September 30, 2022, compared to a profit of HKD 1.8 million for the same period in 2021[65] Assets and Liabilities - Total assets decreased to HKD 25,744,000 as of September 30, 2022, down from HKD 30,091,000 as of March 31, 2022[9] - The company's net asset value was HKD 10,866,000 as of September 30, 2022, compared to HKD 14,179,000 as of March 31, 2022[9] - The company’s total liabilities as of September 30, 2022, were HKD 28,266,000, slightly down from HKD 29,863,000 as of March 31, 2022[9] - Total equity as of September 30, 2022, was HKD 10.9 million, down from HKD 14.2 million as of March 31, 2022[81] Cash Flow - The operating cash generated was HKD 862 thousand, down from HKD 1,860 thousand in the previous year, reflecting a decline of 53.8%[14] - The net cash used in investing activities was HKD (758) thousand, compared to HKD (1,547) thousand in the prior year, indicating a reduction of 51%[14] - The net cash used in financing activities was HKD (3,851) thousand, a decrease from HKD (13,945) thousand in the previous year, showing a significant improvement[14] - Cash and bank balances as of September 30, 2022, were HKD 9.8 million, a decrease from HKD 14.2 million as of March 31, 2022[81] Employee Costs - The company incurred employee costs of HKD 10,420,000 for the six months ended September 30, 2022, a decrease of 10.1% from HKD 11,591,000 for the same period in 2021[4] - Total employee costs amounted to HKD 10,420 thousand, a decrease from HKD 11,591 thousand in the previous year, indicating a reduction of 10.1%[26] - Employee costs decreased by HKD 1.2 million or 10.1% to HKD 10.4 million for the six months ended September 30, 2022, compared to HKD 11.6 million for the same period in 2021[72] Revenue Breakdown - The revenue breakdown includes medical consultation services at HKD 0.5 million (2.5%), prescription and dispensing services at HKD 4.4 million (22.2%), and treatment services at HKD 15.1 million (75.3%) for the six months ended September 30, 2022[64] - The group's revenue for the six months ended September 30, 2022, decreased by HKD 6.6 million or 24.8% to HKD 20.0 million, compared to HKD 26.6 million for the same period in 2021[69] Government Support - The group received government subsidies of HKD 829 thousand under the "Employment Support Scheme" to mitigate the impact of the COVID-19 pandemic[25] Share Capital and Options - The company had 396,736,000 ordinary shares in issue as of September 30, 2022, with a share capital of HKD 3,967,000[41] - No share options were exercised or cancelled during the six months ended September 30, 2022, and 4,000,000 share options expired during the same period[49] - The share options plan details indicate a total of 2,800,000 options available as of September 30, 2022[94] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial statements for the six months ending September 30, 2022, and found them compliant with applicable accounting standards and GEM listing rules[108] - The company has adopted the corporate governance code as per GEM listing rules and has complied with it during the six months ending September 30, 2022[101] Future Outlook - Despite the challenges posed by the COVID-19 pandemic, the company remains cautiously optimistic about future performance due to a solid customer base and good reputation in the industry[67] - The company aims to introduce new services and products as a key driver for business growth and to maintain competitiveness in the market[67] - The group continues to focus on enhancing online consultation services and e-commerce platforms for skincare products to adapt to the new normal[64] Miscellaneous - The company did not recommend an interim dividend for the six months ended September 30, 2022, compared to no dividend in 2021[31] - The group had no significant investments or capital asset plans as of September 30, 2022[83] - The group had no significant contingent liabilities as of September 30, 2022[88] - No significant events occurred after the reporting period[60] - The company has not disclosed any new strategies or market expansions in the provided documents[96] - The company has not reported any violations of the trading rules for directors during the six months ending September 30, 2022[104] - No directors or major shareholders were aware of any direct or indirect business interests that could compete with the group as of September 30, 2022[100]

Financial Performance - The company reported unaudited revenue of HKD 10,467,000 for the three months ended June 30, 2022, a decrease of 23.8% compared to HKD 13,646,000 for the same period in 2021[5]. - The loss before tax for the period was HKD 799,000, compared to a profit of HKD 1,571,000 in the previous year[5]. - The company experienced a significant decline in revenue from treatment services, which amounted to HKD 8,165,000, down 25.4% from HKD 10,949,000 in the prior year[14]. - Revenue from prescription and dispensing services decreased to HKD 2,077,000, a decline of 11.7% from HKD 2,354,000 in the same quarter of 2021[14]. - The company reported a basic and diluted loss per share of HKD 0.20 for the quarter, compared to earnings of HKD 0.38 per share in the previous year[5]. - The total comprehensive loss attributable to owners of the company was HKD 792,000, compared to a comprehensive income of HKD 1,529,000 in the same period last year[5]. - For the three months ended June 30, 2022, the company's revenue decreased by HKD 3.1 million or 22.8% to HKD 10.5 million compared to the same period in 2021[34]. - The company recorded a loss attributable to owners of HKD 0.8 million for the three months ended June 30, 2022, compared to a profit of HKD 1.5 million for the same period in 2021[36]. - The group's revenue decreased by HKD 3.1 million or 22.8% from HKD 13.6 million for the three months ended June 30, 2021, to HKD 10.5 million for the three months ended June 30, 2022, primarily due to the negative impact of the fifth wave of the COVID-19 pandemic and intense market competition[39]. - Other income, gains, and losses netted a loss of HKD 0.043 million for the three months ended June 30, 2022, a decrease of HKD 0.4 million or 66.7% from a net income of HKD 0.3 million for the same period in 2021, mainly due to unrealized exchange losses and the net impact of government subsidies[40]. Assets and Liabilities - The company’s total assets as of June 30, 2022, were HKD 16,657,000, a decrease from HKD 23,445,000 as of June 30, 2021[7]. - The cost of used inventory for the three months ended June 30, 2022, was HKD 2.0 million, representing 18.7% of the revenue, compared to HKD 2.2 million or 16.3% of the revenue for the same period in 2021[41]. - Employee costs decreased by HKD 0.7 million or 12.5% from HKD 5.6 million for the three months ended June 30, 2021, to HKD 4.9 million for the same period in 2022, primarily due to reduced salaries and bonuses linked to decreased revenue[42]. - Other expenses decreased by HKD 0.3 million or 14.3% from HKD 2.1 million for the three months ended June 30, 2021, to HKD 1.8 million for the same period in 2022, primarily due to reduced revenue[46]. Business Strategy and Operations - The company is focused on providing medical consultation services, prescription and dispensing services, and treatment services as its main business segments[12]. - The company has implemented measures to enhance online consultation services and e-commerce platforms for its skincare products[34]. - The board believes that introducing new services and products is one of the key drivers for business growth and maintaining competitiveness in the industry[37]. - The group will continue to adopt a cautious approach to business strategy due to uncertainties and challenges posed by the COVID-19 pandemic[37]. - The company aims to leverage its solid customer base and good reputation in the industry to provide high-quality medical skin care services and products, thereby solidifying its market position and seeking new business opportunities[37]. Governance and Compliance - The board of directors confirmed that the financial statements are accurate and complete, with no misleading or fraudulent elements[3]. - The company adopted the corporate governance code as per GEM Listing Rules Appendix 15 and has complied with it for the three months ending June 30, 2022[59]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements for the three months ending June 30, 2022, ensuring compliance with applicable accounting standards and GEM Listing Rules[66]. - The roles of the chairman and CEO are held by the same individual, Dr. Jiang, to enhance business strategy implementation and operational efficiency[61]. - The board of directors is committed to maintaining a positive relationship between executive and non-executive directors, ensuring collective responsibility for business strategy[61]. - The company encourages active participation from all directors in board affairs to align with the best interests of the company[61]. - The company has not reported any violations of the securities trading rules for directors during the three months ending June 30, 2022[62]. Dividends and Share Options - The company did not declare an interim dividend for the three months ended June 30, 2022, compared to a special dividend of HKD 9,918,000 declared in 2021[26][25]. - As of June 30, 2022, there were 4,000,000 unexercised share options outstanding, unchanged from the previous year[65]. - The company has established a share option scheme to reward eligible individuals for their contributions, in line with GEM Listing Rules[65]. Market Conditions - The company faced significant competition in the market and was impacted by strict social distancing measures due to the fifth wave of COVID-19 in Hong Kong[34]. - The company received government subsidies of HKD 576,000 under the "Employment Support Scheme" to alleviate the impact of the COVID-19 pandemic[20][21]. - There were no significant events occurring after the reporting period[30]. - The depreciation of right-of-use assets remained stable at HKD 1.8 million for the three months ended June 30, 2022, compared to HKD 1.9 million for the same period in 2021[44]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[63]. - No securities transactions were conducted by the company or its subsidiaries during the three months ending June 30, 2022[63].

Financial Performance - The group's revenue for the fiscal year ended March 31, 2022, was HKD 49.1 million, an increase of 17.8% compared to HKD 41.7 million in the previous fiscal year[9]. - The profit attributable to owners of the company was HKD 3.9 million, a significant increase of 311.5% from HKD 1.0 million for the year ended March 31, 2021[9]. - Basic earnings per share for the year were HKD 0.99, representing an increase of 330.4% from HKD 0.23 in the previous year[9]. - The group's revenue increased by HKD 7.4 million or 17.8% from HKD 41.7 million for the year ended March 31, 2021, to HKD 49.1 million for the year ended March 31, 2022[16]. - The profit attributable to the company's owners increased by HKD 3.9 million, a 311.5% increase compared to HKD 1.0 million for the year ended March 31, 2021[18]. Operational Challenges - The company faced challenges due to the COVID-19 pandemic, which affected local economic activities and consumer sentiment[8]. - The group has adopted stricter operational cost controls to mitigate the negative impact of the pandemic on business operations[8]. - The company did not recognize revenue of HKD 0.7 million from the sale of a subsidiary and did not receive government subsidies of HKD 2.3 million during the year[9]. - The group will adopt a cautious approach to business strategy due to uncertainties related to the COVID-19 pandemic[19]. Employee and Cost Management - Employee costs rose by HKD 1.3 million or 6.8% from HKD 19.2 million to HKD 20.5 million due to increased salaries and performance bonuses[23]. - Other expenses increased by HKD 0.5 million or 7.3% from HKD 7.7 million to HKD 8.2 million, attributed to professional fees related to potential business collaborations or acquisitions[26]. - Employee costs for the year ended March 31, 2022, amounted to HKD 20.5 million, an increase from HKD 19.2 million in 2021[51]. Business Strategy and Development - The company aims to explore and launch various new services and products to increase market share and identify new business opportunities[10]. - The group plans to continue market research on new products and technologies to drive business growth and maintain competitiveness[19]. - The company continues to focus on maintaining high-quality service standards and prioritizing customer safety and well-being[10]. Financial Position - As of March 31, 2022, the total equity of the group was HKD 14.2 million, down from HKD 20.0 million in 2021, indicating a decrease of 29%[30]. - The group's cash and bank balances as of March 31, 2022, were HKD 14.2 million, a decrease from HKD 29.4 million in 2021, representing a decline of 52%[30]. - Operating cash generated for the year ended March 31, 2022, was HKD 4.3 million, down from HKD 9.0 million in 2021, reflecting a decrease of 52%[30]. - The group's lease liabilities as of March 31, 2022, amounted to HKD 18.7 million, an increase from HKD 6.4 million in 2021, showing a rise of 192%[30]. Corporate Governance - The company has established an audit committee in compliance with GEM listing rules, which reviewed the audited consolidated financial statements for the year ending March 31, 2022, ensuring compliance with applicable accounting standards[100]. - The board consists of four executive directors and three independent non-executive directors as of March 31, 2022[111]. - The company has adopted corporate governance practices in line with GEM listing rules and has not identified any deviations during the reporting period[109]. - The board is collectively responsible for corporate governance duties, including reviewing and monitoring compliance with laws and regulations[122]. Shareholder Communication - The company has established a shareholder communication policy to ensure timely and comprehensive information dissemination to shareholders and investors, which is reviewed at least annually[157]. - The company holds annual general meetings to provide opportunities for shareholders to communicate with the board and management, with voting procedures clearly outlined[160]. - The company allows shareholders holding at least 10% of the paid-up capital to request the board to convene a special general meeting[164]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes the importance of corporate social responsibility and aims to fulfill its responsibilities towards individuals, communities, and the environment[178]. - The board reviews the company's environmental, social, and governance (ESG) performance annually and identifies related risks[178]. - The company aims to integrate sustainable development into its core business values moving forward[181]. - The company has identified six key stakeholder groups, including shareholders, government, business partners, customers, employees, and the public, and maintains ongoing communication with them[185].

第 季度 報告 2021/2022 MEDIC · SKIN MEDICSKIN HOLDINGS LIMITED 密迪斯肌控股有限公司 (於開曼群島註冊成立之有限公司) 股份代號：8307 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所 上市的公司帶有較高投資風險。有意投資者應了解投資於該等公司的潛在風險，並 應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之 證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市 場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不會就因本報告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其中 載有遵照聯交所GEM證券上巿規則（「GEM上巿規則」）所規定有關本公司的資料。董 事在作出一切合理查詢後確認，就彼等所深知及確信，本報告所載資料在各重大方 面 ...

中期 報告 2021/2022 ■ MEDIC SKIN MEDICSKIN HOLDINGS LIMITED 密迪斯肌控股有限公司 (於開曼群島註冊成立之有限公司) 股份代號：8307 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所 上市的公司帶有較高投資風險。有意投資者應了解投資於該等公司的潛在風險，並 應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之 證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的 市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不會就因本報告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其中 載有遵照聯交所GEM證券上巿規則（「GEM上巿規則」）所規定有關本公司的資料。董 事在作出一切合理查詢後確認，就彼等所深知及確信，本報告所載資料在各重大方 面均屬 ...

Financial Performance - For the three months ended June 30, 2021, the company reported total revenue of HKD 13,646,000, an increase of 31.8% compared to HKD 10,372,000 for the same period in 2020[4] - The profit attributable to the owners of the company for the first quarter was HKD 1,509,000, representing a 72.8% increase from HKD 873,000 in the previous year[4] - Basic and diluted earnings per share for the quarter were both HKD 0.38, up from HKD 0.18 in the same quarter of the previous year[5] - The company recorded a total comprehensive income of HKD 1,494,000 for the quarter, compared to HKD 888,000 in the previous year[4] - The company's revenue for the three months ended June 30, 2021, increased by HKD 3.2 million or 30.8% to HKD 13.6 million compared to the same period in 2020[32] - The profit attributable to the company's owners increased by 66.7% to HKD 1.5 million from HKD 0.9 million in the same period last year[34] - Basic earnings per share for the period were HKD 0.38, compared to HKD 0.18 in the previous year[34] - The net profit attributable to the company's owners rose by HKD 0.6 million or 66.7% from HKD 0.9 million to HKD 1.5 million for the three months ended June 30, 2021[46] Revenue Breakdown - Revenue from medical consultation services was HKD 343,000, an increase of 20.8% from HKD 284,000 in the prior year[12] - Revenue from prescription and dispensing services was HKD 2,354,000, a slight increase of 5.1% compared to HKD 2,240,000 in the previous year[12] - Revenue from treatment services surged to HKD 10,949,000, a significant increase of 39.5% from HKD 7,848,000 in the same quarter of 2020[12] - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.5%, 17.3%, and 80.2% of total revenue, respectively[32] Assets and Liabilities - The company’s total assets as of June 30, 2021, were HKD 19,991,000, reflecting a decrease from HKD 30,401,000 as of June 30, 2020[7] - The cost of used inventory for the three months ended June 30, 2021, was HKD 2.2 million, representing 16.3% of the related period's revenue[39] - Employee costs increased by HKD 0.9 million or 19.1% from HKD 4.7 million to HKD 5.6 million, attributed to higher salaries and performance bonuses due to increased revenue[40] Business Strategy and Future Plans - The company plans to continue focusing on expanding its medical consultation and treatment services to drive future growth[10] - The group plans to continue introducing new services and products to drive business growth and maintain competitiveness in the industry[35] - The group aims to maximize revenue and improve operational efficiency despite ongoing challenges from the COVID-19 pandemic[35] - The group will continue to seek new business opportunities to enhance its brand and provide maximum returns to investors[35] Compliance and Governance - The board confirmed that the financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, ensuring compliance and accuracy[9] - The audit committee, consisting of three independent non-executive directors, reviewed the group's financial statements and confirmed compliance with applicable accounting standards and regulations[64] Special Events and Other Information - The company declared a special dividend of HKD 0.025 per share, totaling HKD 9,918,000, which was distributed on July 26, 2021[22] - The company has implemented video consultation services and delivery for skincare and certain medications in response to the adverse economic conditions due to the COVID-19 pandemic[31] - The company received government subsidies related to the COVID-19 pandemic, which included commitments to retain employees during the subsidy period[18] - The group has entered into a lease agreement for a property in Hong Kong, with a right-of-use asset recognized at HKD 6.9 million[47] - As of June 30, 2021, Dr. Jiang holds a controlling interest in 274,865,400 shares, representing 69.28% of the issued share capital[49] - The company did not purchase, sell, or redeem any of its listed securities during the three months ended June 30, 2021[61] - As of June 30, 2021, there were a total of 4,000,000 unexercised share options, all of which were vested and could be issued as ordinary shares[63]